Nationwide Children's News Releases
Viewing: 21-30 of 99 | All
Nov 23, 2020
Andelyn Biosciences Breaks Ground for New Commercial-Scale Gene Therapy Manufacturing Facility
Andelyn Biosciences, an affiliate company of Nationwide Children’s Hospital that manufactures gene therapy products for the biotechnology and pharmaceutical industries, has broken ground on its new site located at 1250 Arthur E. Adams Dr. in The Ohio State University’s Innovation District. Opening in 2022, it will be central Ohio’s first commercial-scale Good Manufacturing Practices (cGMP) production facility devoted to gene therapies.
Oct 19, 2020
Jerry R. Mendell, MD, Elected to the Prestigious National Academy of Medicine
(COLUMBUS, Ohio) – Today, Jerry R. Mendell, MD, principal investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, was elected to the National Academy of Medicine (NAM), the second faculty member from Nationwide
May 01, 2020
Nationwide Children’s Hospital Names CEO of Andelyn Biosciences
Nationwide Children's Hospital is pleased to announce Mayo Pujols as CEO of Andelyn Biosciences, an affiliate company that will manufacture gene therapy products for the biotechnology and pharmaceutical industries.
Jan 13, 2020
Nationwide Children’s Hospital Announces Plans for Andelyn Biosciences
Central Ohio’s first commercial-scale gene therapy Good Manufacturing Practices (cGMP) clinical manufacturing facility slated for 2023.
May 29, 2019
Nationwide Children’s Hospital Named a CMT Center of Excellence
The Charcot-Marie-Tooth Association has named Nationwide Children’s Hospital a CMT Center of Excellence, in recognition of the comprehensive care and expertise provided to children with the most common form of Charcot-Marie-Tooth disease, CMT1A.
May 24, 2019
FDA Approves First Gene Therapy Treatment for SMA Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital
Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its approval of Zolgensma® for spinal muscular atrophy (SMA) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.
May 21, 2019
Nationwide Children’s Hospital Dedicates Abigail Wexner Research Institute at Nationwide Children’s Hospital
Nationwide Children’s Hospital dedicated the hospital’s Research Institute as the Abigail Wexner Research Institute at Nationwide Children’s Hospital. This naming recognizes Mrs. Wexner, whose ongoing, passionate advocacy has ushered in a period of unprecedented transformation at the hospital.
May 20, 2019
MEDIA ADVISORY: Dedication of the Abigail Wexner Research Institute at Nationwide Children’s Hospital
WHAT: The dedication of the Abigail Wexner Research Institute at Nationwide Children’s Hospital and announcement of the Allen Distinguished Scholar in Pediatric Research WHEN: Tuesday, May 21, 2019 10:30 a.m. – Media Tour of the Abigail Wexner Research Institute 11:30 a.m.
Apr 01, 2019
Anne M. Connolly, MD, Named Division Chief of Neurology at Nationwide Children’s Hospital
Anne M. Connolly, MD, has joined Nationwide Children’s Hospital as division chief of Neurology and a member of the Center for Gene Therapy.
Jan 25, 2019
Nationwide Children’s Hospital Announces Plans to Dedicate the Abigail Wexner Research Institute
Ms. Wexner’s partnership with her fellow board members, Chief Executive Officer Steve Allen, MD, and the Nationwide Children’s executive team made this evolution possible. In recognition of Dr. Allen’s role, Nationwide Children’s will also establish the Allen Distinguished Scholar in Pediatric Research.